Founded in 2010, Boehringer Ingelheim Venture Fund is a venture capital firm that focuses on investing in biotechnology companies driving innovation in biomedical research. The firm seeks to enhance patient care through pioneering science and clinical translation, building long-term relationships with scientists and entrepreneurs. Their investment areas include immuno-oncology, regenerative medicine, infectious diseases, and digital health, with a particular interest in novel therapeutic concepts and technologies. Some of their portfolio startups include Promethera Biosciences, Wellth, and Tacalyx.